Literature DB >> 31196486

The overuse of radioactive iodine in low-risk papillary thyroid cancer patients.

Ambria S Moten1, Huaqing Zhao2, Alliric I Willis3.   

Abstract

BACKGROUND: The aim of this study was to use current American Thyroid Association (ATA) management guidelines to identify groups who might be at risk of overtreatment with radioactive iodine (RAI) ablation after surgery for low-risk papillary thyroid cancer (PTC).
METHODS: PTC patients were identified using the Surveillance, Epidemiology and End Results database. Characteristics of low-risk patients (defined as T1 without metastasis) were compared to those not low-risk. Predictors of receiving RAI for low-risk disease were determined using logistic regression.
RESULTS: Of 32,229 cases, 17,286 (53.6%) were low-risk. Low-risk patients, compared to others, were older (mean age 51.3 versus 48.5 years), and more often female (81.6% versus 71.7%), white (69.7% versus 62.0%), and insured (87.6% versus 85.6%)(all p-values < 0.001). Nearly 25% of low-risk patients received RAI. Predictors of overtreatment with RAI included age <45 years (OR: 1.393; 95% CI: 1.250-1.552), age 45-64 years (OR: 1.275; 95% CI: 1.152-1.412), male sex (OR: 1.191; 95% CI: 1.086-1.305), Hispanic (OR: 1.236; 95% CI: 1.110-1.376) and Asian (OR: 1.306; 95% CI: 1.159-1.473) race, and extensive lymphadenectomy (OR: 1.243; 95% CI: 1.119-1.381).
CONCLUSION: Low-risk PTC patients were more likely to receive post-surgical RAI when not indicated under ATA guidelines if they were younger, male, Hispanic or Asian, or underwent extensive lymph node surgery. Identification of groups at risk for overtreatment can help impact practice patterns and improve the effective utilization of healthcare resources.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Overtreatment; Radioactive iodine; Thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 31196486     DOI: 10.1016/j.suronc.2019.05.011

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

1.  Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer.

Authors:  Miranda Mittica; Andrea Dotto; Martina Comina; Marsida Teliti; Eleonora Monti; Massimo Giusti
Journal:  Thyroid Res       Date:  2020-01-10

2.  The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice.

Authors:  Krzysztof Kaliszewski; Dorota Diakowska; Łukasz Nowak; Beata Wojtczak; Jerzy Rudnicki
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

3.  Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.

Authors:  Hengqiang Zhao; Yiping Gong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

Review 4.  Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival.

Authors:  Jolanta Krajewska; Aleksandra Kukulska; Malgorzata Oczko-Wojciechowska; Agnieszka Kotecka-Blicharz; Katarzyna Drosik-Rutowicz; Malgorzata Haras-Gil; Barbara Jarzab; Daria Handkiewicz-Junak
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-06       Impact factor: 5.555

5.  The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.

Authors:  Domenico Albano; Francesco Dondi; Valentina Zilioli; Maria Beatrice Panarotto; Alessandro Galani; Carlo Cappelli; Francesco Bertagna; Raffaele Giubbini; Claudio Casella
Journal:  Ann Nucl Med       Date:  2021-06-21       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.